Low Dose NaltrexoneLDN for Chronic Pain & Neuroinflammation
An inexpensive, well-tolerated, off-label oral medication that works through a completely different mechanism than conventional pain drugs — targeting the neuroinflammation that drives fibromyalgia, CRPS, and a growing list of chronic conditions.
Low Dose Naltrexone — An Old Drug With a New Purpose
Naltrexone is an FDA-approved opioid antagonist used since the 1980s at doses of 50–100 mg daily to treat opioid and alcohol use disorders. At these standard doses it works by fully blocking opioid receptors.
At much lower doses — typically 0.5 to 4.5 mg daily — naltrexone does something entirely different. Instead of sustained receptor blockade, the brief, transient blockade at low doses triggers a compensatory rebound increase in the body's own endorphin production. More importantly, at these low doses naltrexone also acts as a Toll-like receptor 4 (TLR4) antagonist — a mechanism completely independent of its opioid effects.
This TLR4 action silences overactivated microglial cells in the central nervous system — the primary driver of neuroinflammation underlying fibromyalgia, CRPS, and many other centralized pain conditions. This dual mechanism makes LDN unlike any other medication currently available for chronic pain.
Cost advantage: Because naltrexone is a decades-old generic medication, compounded low-dose naltrexone typically costs just $20–60 per month — making it one of the most accessible treatments in our regenerative medicine toolkit.
| Dose Range | Primary Use | Mechanism |
|---|---|---|
| 50–100 mg/day | Opioid/alcohol use disorder (FDA-approved) | Sustained full opioid receptor blockade |
| 4.5 mg/day | Fibromyalgia, CRPS, MS (off-label) | Transient opioid blockade + TLR4 inhibition |
| 1.5–3 mg/day | Starting / titration dose | Same dual mechanism at lower intensity |
| 0.5–1 mg/day | Highly sensitive patients / initial trial | Minimum effective glial modulation |
How LDN Works — Three Distinct Mechanisms
LDN's effects on chronic pain and neuroinflammation are mediated by three synergistic mechanisms — each one distinct from how conventional pain medications work, which is why LDN helps patients who have failed standard treatments.
TLR4 Inhibition & Glial Attenuation
At low doses, naltrexone blocks Toll-like receptor 4 (TLR4) on microglial cells — the brain and spinal cord's resident immune cells. TLR4 activation drives chronic neuroinflammation: the sustained, low-grade central nervous system inflammation that underlies fibromyalgia, CRPS, and many centralized pain conditions. By silencing TLR4, LDN reduces production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 in the CNS. This mechanism is completely independent of opioid receptor activity and unique to low doses.
Endorphin Rebound Upregulation
The brief, transient blockade of opioid receptors by LDN (lasting only a few hours) sends a signal to the brain that endorphin levels are low. In response, the body compensatorily upregulates production of endogenous opioids — including beta-endorphin and met-enkephalin (also called Opioid Growth Factor, or OGF). This rebound increase in endorphin tone persists long after LDN has cleared the system, providing sustained analgesic and mood-enhancing effects throughout the day.
OGF–OGFr Axis & Cell Regulation
Met-enkephalin (OGF) acts on the OGF receptor (OGFr) to regulate cellular proliferation and immune modulation. LDN transiently blocks OGFr, which causes compensatory upregulation of both OGF and OGFr. The enhanced OGF–OGFr signaling that follows inhibits abnormal cellular proliferation and modulates immune function — a mechanism with implications for autoimmune conditions and potentially cancer. This pathway also contributes to LDN's anti-inflammatory effects in Crohn's disease, multiple sclerosis, and related conditions.
A Brief History of LDN
The FDA approved naltrexone (brand name Trexan, later ReVia) at 50 mg daily for opioid use disorder. It became a cornerstone of addiction medicine with a well-established safety record built over decades.
New York physician Dr. Bernard Bihari began treating AIDS patients with naltrexone at doses of 1.5–4.5 mg. He observed unexpected immune-modulating effects and noted improvements in patients with autoimmune conditions and cancer — the first clinical observations of LDN's non-opioid mechanisms.
Dr. Jill Smith at Penn State published landmark trials demonstrating LDN's efficacy in Crohn's disease. Simultaneously, researchers began identifying the TLR4 mechanism, explaining why LDN's effects at low doses differ so dramatically from its behavior at standard doses.
Dr. Jarred Younger at Stanford published the first RCT demonstrating LDN's efficacy specifically for fibromyalgia pain, reporting a 29% reduction in pain scores vs. 18% on placebo. This landmark study shifted the focus toward chronic pain applications and catalyzed a generation of LDN research.
Multiple systematic reviews, meta-analyses, and RCTs now support LDN for fibromyalgia, CRPS, multiple sclerosis, Crohn's disease, and other conditions. A 2025 meta-analysis presented at ACR Convergence confirmed significant pain reduction and functional improvement in fibromyalgia. LDN has gone from fringe to mainstream in integrative and regenerative medicine.
What Can LDN Treat?
LDN's anti-neuroinflammatory mechanism makes it relevant across a surprisingly wide range of conditions where glial activation and central sensitization play a role.
Fibromyalgia
Strongest evidence base for LDN in pain management. Multiple RCTs and a 2025 ACR meta-analysis confirm significant pain reduction and functional improvement.
Complex Regional Pain Syndrome (CRPS)
Postmortem studies have confirmed TLR4 upregulation and microglial overactivation in CRPS spinal cord — the exact target of LDN. Case series and clinical reports show meaningful benefit.
Multiple Sclerosis
Several trials demonstrate quality-of-life improvement, fatigue reduction, and possible neuroprotective effects. One of the best-studied off-label uses of LDN.
Crohn's Disease & IBD
RCTs including pediatric trials demonstrate significant disease activity reduction and mucosal healing. Strong mechanistic rationale through OGF-mediated gut immune modulation.
Chronic Neuropathic Pain
Diabetic neuropathy, post-herpetic neuralgia, and other neuropathic conditions driven by central sensitization respond to LDN's glial modulation.
Chronic Fatigue Syndrome (ME/CFS)
Neuroinflammation and glial activation are implicated in ME/CFS. Clinical reports and emerging studies suggest LDN reduces fatigue and cognitive symptoms.
Long COVID Pain & Fatigue
Growing evidence that LDN's TLR4-mediated microglial silencing addresses neuroinflammation driving Long COVID symptoms including pain, fatigue, and brain fog.
Autoimmune Conditions
Hashimoto's thyroiditis (documented antibody reduction), psoriasis, rheumatoid arthritis, and lupus — LDN's immune-modulating effects show promise across autoimmune disease.
Chronic Low Back Pain
Central sensitization contributes significantly to chronic back pain. LDN's ability to reduce glial activation and neuroinflammation provides a rational complement to other interventions.
Treatment-Resistant Depression
LDN's dual mechanism — increasing endorphin tone and reducing microglial neuroinflammation — provides growing rationale for use in depression, anxiety, and PTSD resistant to standard therapy.
Chronic Pelvic Pain / Interstitial Cystitis
Centrally mediated pelvic pain conditions with neuroinflammatory components respond to LDN's glial-modulating effects in clinical practice.
Parkinson's Disease (Adjunct)
Neuroinflammation and microglial activation are central to Parkinson's pathology. Preclinical and early clinical data suggest possible neuroprotective benefit from LDN.
Why LDN Is Emerging as a First-Line Option for Fibromyalgia
Fibromyalgia affects an estimated 4 million Americans and is characterized by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive dysfunction. The underlying mechanism is now understood to be central sensitization — a state of amplified, dysregulated pain processing driven in large part by microglial activation and neuroinflammation in the central nervous system.
This is precisely where LDN excels. By silencing overactivated microglial cells through TLR4 inhibition and upregulating endorphin tone, LDN directly addresses the pathophysiologic processes underlying fibromyalgia that are largely unaddressed by current FDA-approved therapies (pregabalin, duloxetine, milnacipran).
A 2025 systematic review and meta-analysis presented at ACR Convergence (Rizwan et al.) — analyzing all available RCTs through December 2024 — found LDN significantly reduced fibromyalgia pain scores (pooled SMD –0.851) and improved functional outcomes on the Fibromyalgia Impact Questionnaire Revised (SMD –0.978) compared to placebo, with a favorable adverse event profile.
Why LDN Deserves Serious Consideration
Three medications are FDA-approved for fibromyalgia — pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran (Savella). None address the underlying neuroinflammatory mechanism. LDN offers a different and potentially complementary approach.
⚠ Conventional Fibromyalgia Drugs
✓ Low Dose Naltrexone (LDN)
Starting & Taking LDN — A Practical Guide
LDN requires patience and a slow titration approach. Most patients do not see full benefit immediately — response builds over weeks to months as neuroinflammation is gradually suppressed.
Dosing & Titration Protocol
- Start low: 0.5–1.5 mg at bedtime to minimize initial side effects
- Increase by 0.5–1 mg every 2–4 weeks based on response and tolerability
- Target dose for most pain conditions: 1.5–4.5 mg once daily
- Most patients find their optimal dose between 3–4.5 mg
- If vivid dreams are problematic, switch to morning dosing
- Allow 3–6 months at therapeutic dose before assessing full response
- LDN must be compounded by a compounding pharmacy — it is not commercially available at these doses
Important Drug Interactions
- Opioid medications: LDN is contraindicated with opioids — it will precipitate withdrawal. Patients must be opioid-free for at least 7–10 days before starting LDN
- Immunosuppressants: LDN's immune-modulating effects may interact with immunosuppressive therapies — discuss with your physician
- Thyroid medications: LDN does not interfere with thyroid hormones based on available evidence
- NSAIDs, antidepressants, anticonvulsants, and most other pain medications are compatible with LDN
- Inform all providers that you are taking LDN before any procedure or new prescription
Signs That LDN Is Working
- Gradual reduction in pain intensity over weeks to months
- Improved sleep quality — often one of the earliest signs
- Reduced fatigue and improved cognitive clarity
- Less frequent or severe flares
- Improved mood and emotional resilience
- Ability to reduce doses of other pain or sleep medications
- Increased daily function and activity tolerance
Monitoring & Follow-Up
- Initial follow-up at 4–6 weeks to assess early tolerability and adjust dose
- 3-month assessment: evaluate pain scores, sleep, fatigue, and function
- 6-month formal response assessment using validated outcome measures
- Liver function monitoring recommended periodically (naltrexone is hepatically metabolized)
- If no response after 6 months at 4.5 mg, LDN is unlikely to be effective and should be discontinued
- Responders may continue indefinitely — long-term safety profile is excellent
Benefits & Risks of LDN Therapy
Contraindications & Precautions
LDN has a favorable safety profile but must not be used in patients currently taking opioid medications. A thorough medication review is essential before prescribing.
Current Opioid Use Absolute
LDN will precipitate acute opioid withdrawal in opioid-dependent patients. Must be opioid-free for at least 7–10 days. This is a hard stop — no exceptions.
Buprenorphine (Suboxone / Subutex) Absolute
Buprenorphine is a partial opioid agonist. LDN will displace it and precipitate withdrawal. Cannot be used concurrently under any circumstances.
Methadone Absolute
Methadone is a full opioid agonist. LDN is absolutely contraindicated in patients on methadone maintenance therapy.
Acute Opioid Overdose Treatment Absolute
Do not administer LDN to a patient who may have recently taken opioids — withdrawal risk.
Severe Hepatic Impairment Relative
Naltrexone is hepatically metabolized. Use with caution in liver disease; monitor liver function regularly.
Concurrent Immunosuppressive Therapy Relative
LDN's immune-modulating effects may interact with immunosuppressants. Discuss risk-benefit with your physician if on transplant immunosuppression or biologic therapy.
Pregnancy & Breastfeeding Relative
Insufficient safety data. Not recommended during pregnancy or while breastfeeding.
Anticipated Surgery with Opioid Anesthesia Relative
LDN must be held for at least 72 hours before surgery requiring opioid anesthesia or post-operative opioid analgesia. Inform your anesthesiologist.
Key Published Evidence
Our LDN protocols are based on the best available evidence. The field is evolving rapidly — the studies below represent the strongest published support as of 2025.
LDN Meta-analysis for Fibromyalgia | ACR Convergence 2025
Rizwan, Grewal, Banda, Hazique. Five RCTs analyzed. LDN significantly reduced pain scores (pooled SMD –0.851; 95% CI –1.290 to –0.412) and improved functional outcomes on the FIQR (SMD –0.978). Authors concluded LDN's dual mechanism addresses key pathophysiologic processes in fibromyalgia largely unaddressed by current therapies.
Clinical Advisor SummaryLDN Safety & Efficacy Systematic Review — Fibromyalgia | PMC 2023
Dove Medical Press systematic review concluded LDN appears to be a safe and effective option for fibromyalgia management. Reviewed all available studies noting consistent safety signal and promising efficacy, with calls for larger well-designed RCTs.
View Full Text (PMC)LDN as Novel Anti-inflammatory for Chronic Pain | PMC (Younger et al.)
Landmark mechanistic paper reviewing evidence that LDN operates as a novel anti-inflammatory agent in the CNS via microglial cell action. This paper established the TLR4 hypothesis and remains foundational to LDN research. Authors note effects are entirely independent of opioid receptor activity and unique to low doses.
View Full Text (PMC)LDN for Centralized Non-Cancer Pain — Scoping Review | Pain Medicine 2023
Oxford Academic scoping review focused specifically on LDN's utility for centralized pain conditions. Confirmed the mechanistic rationale via TLR4/microglial pathways and reviewed clinical evidence across fibromyalgia, CRPS, and related conditions. Supported the use of LDN as a therapeutic option for centralized pain states.
View Article (Oxford)Real-World LDN Cohort — Pain Practice 2024/2025 | PMC
Retrospective cohort of 93 patients prescribed LDN across 12 chronic pain diagnosis groups. Subjective symptom relief reported by 53.8% of patients, with improvements most commonly in pain and fatigue. Fibromyalgia was the largest subgroup (27 patients). Adverse events were minimal and consistent with published literature.
View Full Text (PMC)LDN Therapeutic Review — PMC 2018 (Widely Cited)
Comprehensive review of LDN therapeutic utilization covering the full scope of clinical applications. Describes TLR4 mechanism, OGF-OGFr pathway, and reviews evidence across fibromyalgia, Crohn's, multiple sclerosis, CRPS, and cancer. Remains one of the most comprehensive and widely cited LDN references.
View Full Text (PMC)An honest note on the evidence: LDN is a promising treatment with a compelling mechanistic rationale and growing clinical evidence. However, the evidence base is still developing — several trials have been underpowered, and not all studies have shown significant benefit over placebo (notably, a larger 2024 Lancet Rheumatology RCT found no significant difference at 6 mg). Our physician will discuss the current state of the evidence honestly with you so you can make a fully informed decision about whether LDN is appropriate for your situation.
Interested in LDN for Your Chronic Pain?
Schedule a consultation with our physician to determine whether low dose naltrexone is appropriate for your condition.
Book My ConsultationMedical Disclaimer: Low dose naltrexone is an off-label use of an FDA-approved medication. It has not been FDA-approved for pain, fibromyalgia, or any of the other conditions discussed on this page. Results vary between individuals and are not guaranteed. This page is for informational purposes only and does not constitute medical advice. Candidacy is determined on an individual basis following a comprehensive medical evaluation. All peer-reviewed references are provided for informational purposes and link to publicly available abstracts or full texts.
